NCT03153319View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI
Interventions
DRUG

Adalimumab Injection [Humira]

Investigational Drug

DRUG

Saline Solution for Injection

Placebo Comparator

Trial Locations (1)

90502

The Lundquist Institute at Harbor-UCLA Medical Center, Torrance

All Listed Sponsors
collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

NCT03153319 - Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI | Biotech Hunter | Biotech Hunter